• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 23rd November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

OHE’s Chris Sampson is leading a new Research Topic published in Frontiers in Health Services, titled ‘Opportunity Costs in Health Care: Cost-effectiveness Thresholds and Beyond’. The Research Topic is open for submissions, and the editors are inviting research and commentary…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

OHE’s Chris Sampson is leading a new Research Topic published in Frontiers in Health Services, titled ‘Opportunity Costs in Health Care: Cost-effectiveness Thresholds and Beyond’. The Research Topic is open for submissions, and the editors are inviting research and commentary on a range of issues that the OHE team has been tackling for many years.

OHE’s Chris Sampson is leading a new Research Topic published in Frontiers in Health Services, titled ‘Opportunity Costs in Health Care: Cost-effectiveness Thresholds and Beyond’. The Research Topic is open for submissions, and the editors are inviting research and commentary on a range of issues that the OHE team has been tackling for many years.

Opportunity cost is a fundamental concept in economics. It underlies all that we do and is sometimes the elephant in the room for health technology assessment (HTA). Without a good understanding of opportunity cost, it’s unlikely that health care resources will be allocated fairly and efficiently.

Defining ‘opportunity cost’ is simple enough; it is represented by the value of the choices we don’t make. For instance, the opportunity cost of investing in programme A – if it exhausts our budget – is what we could have achieved with programme B, which could not be provided.

But the reality is not so simple.

We seldom have a clear understanding of the next best alternative for expenditure in health care. The challenge operates on multiple levels. For starters, there is often a great deal of uncertainty – especially for new technologies – which means we cannot be confident about the magnitude of opportunity costs. It is also difficult to predict how an investment will impact on the current provision of care; disinvestment decisions are rarely observed, and changes made by local commissioners are not so clearly defined as the decision problems considered in HTA. Recent research has sought to identify cost-effectiveness thresholds by examining expenditure and outcomes data, but can a fixed threshold represent opportunity costs across diverse technologies and clinical settings?

A new Research Topic for the journal Frontiers in Health Services will bring together disparate strands of research on opportunity costs in health care. The editors – Chris Sampson, Ashley Leech, and Borja Garcia-Lorenzo – are inviting a wide variety of submissions. The overall purpose of the Research Topic is to improve the extent to which opportunity costs can be fully recognised in health care resource allocation decisions. Methodological, theoretical, and applied research studies – both qualitative and quantitative – are all needed to advance policy and practice.

OHE has led research on this top for many years, with a particular focus on cost-effectiveness thresholds. As the first empirical estimates of a cost-effectiveness threshold for England were published in 2013, we shared our concerns about the methods. And we went on to explore some of the assumptions inherent in this approach. In particular, we considered that different providers in different clinical areas might achieve health outcomes with varying levels of efficiency, which may lead to bias and more uncertainty in the estimates than previously acknowledged.

But our interest in thresholds predates the empirical work, and we have been considering economic and ethical issues for many years. We’ve also sought to explore the challenge of understanding opportunity costs from different angles. For example, our research in Wales and in Scotland sought to understand how disinvestment and displacement might operate in the NHS, and what that might mean for opportunity costs.

Cost-effectiveness thresholds are used in different ways around the world, often alongside modifiers that implicitly or explicitly assume a different opportunity cost for certain technologies. With a growing interest in cost-effectiveness thresholds, we’ve been developing new approaches. In particular, we’ve explored the implications of accounting for bargaining power in the identification of a cost-effectiveness threshold.

There’s also the challenge of considering opportunity costs beyond health. To this end, we’ve recently been researching how different government departments value life. Most recently, we’ve been exploring the role of vaccines in maintaining health system capacity; how should we measure opportunity cost when investments may help prevent overloading of the health care system?

In 2016, we published a paper identifying a research agenda for cost-effectiveness thresholds. Some of the topics that we proposed remain under-researched. And cost-effectiveness thresholds are just one way of thinking about opportunity costs; might methods such as multi-criteria decision analysis (MCDA) or programme budgeting and marginal analysis (PBMA) have a role here?

Our new Research Topic seeks to move the debate forward by bringing together leading researchers from within and outside the field of health economics. If you’re currently working on relevant research and would like to contribute, head over to the Research Topic webpage and enter your details.

For more information, contact Chris Sampson at OHE.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • Spotlight on OHE

Related News

  • News
  • May 2020

OHE Awarded Independent Research Organisation (IRO) Status by UKRI

Read more
  • News
  • February 2019

OHE Response to Public Consultation on NICE Principles

Read more
  • News
  • December 2018

OHE Achievements in 2018

Read more
screenshot
  • News
  • May 2018

A New Online Tool for Creating Personal and Social EQ-5D-5L Value Sets

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!